UK markets closed
  • FTSE 100

    +53.54 (+0.76%)
  • FTSE 250

    +283.88 (+1.26%)
  • AIM

    +9.91 (+0.79%)

    -0.0015 (-0.13%)

    +0.0098 (+0.70%)

    -1,438.47 (-3.39%)
  • CMC Crypto 200

    +44.29 (+3.08%)
  • S&P 500

    +30.98 (+0.74%)
  • DOW

    +229.26 (+0.66%)

    -0.08 (-0.12%)

    +0.70 (+0.04%)
  • NIKKEI 225

    +26.42 (+0.09%)

    -26.85 (-0.09%)
  • DAX

    +202.95 (+1.34%)
  • CAC 40

    +28.42 (+0.45%)

2021 Pipeline Insights into Collagen Inhibitors - Featuring Shanghai Genomics, Matrizyme & Roche Among Others -

·4-min read

The "Collagen Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to's offering.

This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Collagen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Collagen inhibitors Understanding

Collagen inhibitors: Overview

Collagen is an essential part of the framework of the design of our various body tissues. It is the major insoluble fibrous protein in the extracellular matrix and in connective tissue.

Function -Collagen is a member of a family of naturally occurring proteins. It is one of the most plentiful proteins present in mammals and it is responsible for performing a variety of important biological functions. It is most well-known for the structural role it plays in the body. It is present in large quantities in connective tissue and provides tendons and ligaments with tensile strength and skin with elasticity. It often works in conjuction with other important proteins such as keratin and elastin.

Collagen inhibitors- Inhibition of collagen formation is an attractive target to reduce excessive formation of fibrotic tissue. Unlike canonical inhibitors of excessive accumulation of collagen-rich deposits, inhibition of collagen fibril formation targets a specific, extracellular event. Blocking collagen fibril formation may serve as an independent or supporting method to reduce excessive, localized accumulation of collagen-rich deposits.Antibody-based inhibitors of collagen fibril formation are promising therapeutic agents with a potential to limit localized fibrosis in a number of tissues.

Collagen inhibitors Emerging Drugs Chapters

This segment of the Collagen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Collagen inhibitors Emerging Drugs

Remlarsen: miRagen Therapeutics

Remlarsen is a microRNA-29 replacement therapy, being developed by miRagen Therapeutics for the treatment of eye disorders. The drug is currently in preclinical stage for the treatment of eye disorders. In preclinical studies Remlarsen treatment appeared to reduce corneal hazing and scarring beginning at 10 days post-burn. Dose and treatment schedule were optimized in preparation for enabling toxicology studies to support human clinical trials.

Hydronidone: Shanghai Genomics

Hydronidone is a Collagen inhibitor being developed by Shanghai Genomics for several indications. The drug is in phase 2 of clinical trial for the treatment of Hepatic fibrosis.

Collagen inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Collagen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Collagen inhibitors

There are approx. 10+ key companies which are developing the Collagen inhibitors. The companies which have their Collagen inhibitors drug candidates in the most advanced stage, i.e. phase 2 include, miRagen Therapeutics.


This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I/II and Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Collagen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion

  • Intradermal

  • Intramuscular

  • Intranasal

  • Intravaginal

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical.

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Collagen inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Collagen inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Collagen inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Collagen inhibitors R&D. The therapies under development are focused on novel approaches for Collagen inhibitors.

Collagen inhibitors Report Insights

  • Collagen inhibitors Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Collagen inhibitors Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Players

  • miRagen Therapeutics

  • Shanghai Genomics

  • Matrizyme

  • Roche

  • NeuMedics

  • Processa Pharmaceuticals

Key Products

  • Remlarsen

  • Hydronidone

  • MZ-004

  • Pirfenidone

  • NM 108

  • Halofuginone

For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900